Montalis (Montelukast Sodium)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth muscle and inflammatory cells. This inhibition prevents leukotriene‑mediated bronchoconstriction, mucus production, and vascular leakage, helping to keep the airways open and less inflamed.

The appropriate dose of Montalis is determined by the prescribing healthcare professional based on the patient’s age, weight, and specific condition. Dosage instructions are individualized and should be followed exactly as written on the prescription label.

Safety data for montelukast in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against risks before prescribing Montalis to pregnant or nursing individuals, and discuss any concerns with the patient.

To request Montalis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montalis belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is especially useful for patients who need additional control of leukotriene‑driven inflammation or who prefer a non‑inhaled option.

Montalis should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Montalis is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with water and not chewed or crushed unless specifically instructed.

Serious risks include neuropsychiatric events such as depression, suicidal thoughts, and rare severe skin reactions like Stevens‑Johnson syndrome or angioedema. Patients should be advised to seek immediate medical attention if they experience mood changes, rash, or swelling of the face or throat.

Montalis is contraindicated in individuals with known hypersensitivity to montelukast or any of its excipients. Caution is also advised for patients with severe hepatic impairment or those taking interacting medications that may alter its effectiveness.